Nuo Therapeutics, Inc. (AURX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Nuo Therapeutics announced Q1 2026 financial results on May 14, 2026, with the full details contained in the accompanying press release (Exhibit 99), though specific financial metrics are not disclosed in the 8-K itself.
The 8-K filing is purely procedural, disclosing earnings results under Item 2.02 without material announcements, executive changes, significant agreements, or other material events that would typically drive stock movement.
The disclaimer explicitly states that the furnished information is not 'filed' under Section 18 and carries no liability protections, limiting the legal weight of the earnings disclosure for securities claims.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-26

Nuo Therapeutics secured a $1.6 million loan facility, with $1 million funded immediately and an additional $600,000 available upon request, to be used for general working capital purposes.
Two of Nuo Therapeutics' major shareholders, Scott M. Pittman and Paul Anthony Jacobs, participated in the loan as lenders, indicating their continued support for the company.
The loan agreement includes various prepayment terms, including mandatory prepayment upon certain events such as an equity financing of at least $5 million or a change in control.

Other reports for Nuo Therapeutics, Inc.

Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.